News | July 12, 2025
Briefs: Emcure Pharmaceuticals and Gland Pharma
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
It is intended for contrast enhancement in MRI scans
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
The company showcased three core programs developed through this platform
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Subscribe To Our Newsletter & Stay Updated
